Synthesis and pharmacological evaluation of 5-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine derivatives as platelet aggregation inhibitors

Add time:07/14/2019    Source:sciencedirect.com

One pot synthesis and characterization of new 5-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridines (3a–k) using amides (2a–k) were reported. The prepared 5-[2′-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4,5,6,7-tetrahydro-thieno[3,2-c]pyridine (3a) is a bioisostere of 4′-(6,7-dihydro-4H-thieno [3,2-c]pyridin-5-ylmethyl)-biphenyl-2-carboxylic acid (1), having good in vivo antithrombotic activity compared with Clopidogrel. The new tetrazole derivatives (3a–k) were screened for their in vitro activity as platelet aggregation inhibitors.

We also recommend Trading Suppliers and Manufacturers of [2-(biphenyl-4-ylmethyl)-4-methyl-4,5-dihydro-1,3-oxazol-4-yl]methanol (cas 37087-05-1). Pls Click Website Link as below: cas 37087-05-1 suppliers

Prev:3-(E)-Styryl-2H-chromene derivatives as potent and selective monoamine oxidase B inhibitors
Next:Synthesis and binding assays of novel 3,3-DIMETHYLPIPERIDINE (cas 1193-12-0) derivatives with various lipophilicities as σ1 receptor ligands)